Eight Houston entrepreneurs are among 16 recipients of EOY’s Gulf South Award, which recognizes leaders of high-growth companies in Central Texas, South Texas, Louisiana, and Mississippi. Photo via Getty Images

Eight Houston-area entrepreneurs have been named regional winners in Ernst & Young’s 2024 Entrepreneur Of The Year program.

The eight entrepreneurs are among 16 recipients of EOY’s Gulf South Award, which recognizes leaders of high-growth companies in Central Texas, South Texas, Louisiana, and Mississippi.

A panel of judges chose the winners based on factors such as:

  • Creation of long-term value through entrepreneurship.
  • Commitment to the purpose of their business.
  • Demonstration of growth and “substantial impact.”

“The 2024 Entrepreneur Of The Year Gulf South Award winners are exceptional business leaders fueling innovation within their industries and growth within their companies,” says Anna Horndahl, an EY partner who is co-director of EOY’s Gulf South program.

The Houston area’s Gulf South winners for 2024 are:

  • Hal Brumfield of Tachus Fiber Internet, a provider of fiber-to-the-home internet service based in The Woodlands.
  • Stuart Hinchen and Peter Jenkins of QuVa Pharma, a Sugar Land-based provider of ready-to-administer injectables.
  • Andrew Levy of Avelo Airlines, a low-cost airline based in Houston.
  • Derek Maetzold of Castle Biosciences, a Friendswood-based provider of diagnostic tests.
  • Shannon Payne of Allied Fire Protection, a Pearland-based provider of fire prevention products and services.
  • John Poindexter of JB Poindexter & Co., a Houston-based provider of automotive and manufacturing goods and services.
  • Ting Qiao of Wan Bridge, a Houston-based developer and operator of build-to-rent communities.

“These entrepreneurs are shining examples of how to lead a scaling business and also care for their employees, customers and communities,” says Travis Garms, an EY partner who is co-director of EOY’s Gulf South program.

The regional winners now qualify for consideration in the EOY national awards program. The national awards are scheduled to be presented in November.

Gaurab Chakrabarti and Sean Hunt were originally named regional winners in this year's competition this summer along with nine other Houston entrepreneurs. Photos via solugen.com

Houston founders named winners for 2023 Entrepreneur of the Year awards

winner, winner

Houston’s Gaurab Chakrabarti and Sean Hunt, the founders of the transformative chemical manufacturing company Solugen, have been named EY’s US National Award winners for Entrepreneur of the Year.

Solugen, also recently named a finalist in the 2023 Houston Innovation Awards, is an environmentally friendly approach that relies on smaller chemical refineries that helps in reducing costs and transportation-related emissions. Some of their noted accomplishments includes innovations like the proprietary reactor, dubbed the Bioforge, which is a carbon-negative molecule factory and manufacturing process produces zero wastewater or emissions compared with traditional petrochemical refineries.The Bioforge uses a chemienzymatic process in converting plant-sourced substances into essential materials that can be used instead of fossil fuels.

Chakrabarti and Hunt were originally named regional winners in this year's competition this summer along with nine other Houston entrepreneurs.

Founded in 2016 by Hunt and Gaurab Chakrabarti, Solugen has raised over $600 million from investors like Sasol that believe in the technology's potential. The company is valued at reportedly over $2 billion. Solugen is headquartered in Houston, not because it is the hometown of Chakrabarti, but for what Houston brings to the company.

“There’s no way our business could succeed in the Bay Area," Chakrabarti said in a 2023 interview at SXSW where he detailed the offers Hunt and he received to move the business out of state. “For our business, if you look at the density of chemical engineers, the density of our potential customers, and the density of people who know how to do enzyme engineering, Houston happened to be that perfect trifecta for us.”

Even though they are headquartered in Houston, Solugen recently secured plans to expand to the Midwest, as in November they announced its newest strategic partnership with sustainable solutions company ADM (NYSE:ADM) in Marshall, Minnesota. The partnership includes plans for Solugen to build a 500,000-square-foot biomanufacturing facility next to an existing ADM facility , with the two companies working together on producing biomaterials to replace fossil fuel products.

“The strategic partnership with ADM will allow Solugen to bring our chemienzymatic process to a commercial scale and meet existing customer demand for our high-performance, cost-competitive, sustainable products,” Chakrabarti said in a news release. “As one of the few scaled-up and de-risked biomanufacturing assets in the country, Solugen’s Bioforge platform is helping bolster domestic capabilities and supply chains that are critical in ensuring the U.S. reaches its ambitious climate targets.”

For Chakrabarti and Hunt, Solugen was born out of a 12-year friendship, and the journey began after a friendly card game. After an entrepreneurship contest at MIT, which earned them second place and a $10,000 prize, they invested the winnings to work on what would become Solugen, a proof-of-concept reactor with materials bought from a local home improvement store.

"We had a conviction that we were building something that could be impactful to the rest of the world,” Chakrabarti said at SXSW in 2023.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”